データなし
データなし
Ensysce Biosciences Secures Commercial Supplier For PF614-MPAR Overdose Protection Drug, Fully Establishing Supply Chain With GMP Nafamostat From Aurore Life Sciences
Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Ensysce Biosciences Initiates PARtnership With A Drug Manufacturer For The Development And Commercial Launch Of PF614 And PF614-MPAR, Including A $10M Commitment From The Drug Manufacturer
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket